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This systematic review and meta-analysis aim to investigate the prevalence rates of various types of sleep
disturbances among head and neck cancer (HNC) patients before, during, and after cancer treatment. We
performed a systematic search on PubMed, Embase, CINAHL, and PsycINFO to find studies that reported
the prevalence of any type of sleep disturbance among adult HNC patients. Meta-analyses of prevalence
were performed using random effects models, with I2 values to indicate the extent of heterogeneity. In
total, 29 studies of accumulatively 2315 HNC patients were included. The quality of the studies was fairly
low and the heterogeneity was high. Studies on three types of sleep disturbances were found: insomnia
(17 studies), hypersomnolence (12 studies), and sleep-related breathing disturbances (14 studies). The
prevalence of insomnia was 29% (95% CI 20e41%) before treatment, 45% (95% CI 33e58%) during
treatment, and 40% (95% CI 24e58%) after treatment, while for hypersomnolence the prevalence was 16%
(95% CI 7e32%) before treatment and 32% (95% CI 20e48%) after treatment. The prevalence of sleep-
related breathing disturbances before and after treatment was 66% (95% CI 44e82%) and 51% (95% CI
34e67%), respectively. These results imply that sleep disturbances are highly prevalent among HNC
patients before, during, and after treatment.
© 2019 Elsevier Ltd. All rights reserved.Introduction
Every year more than half a million people in the world are
diagnosed with head and neck cancer (HNC) [1]. Among this pop-
ulation, sleep disturbances have been hypothesized to be highly
prevalent [2]. Two major risk factors of HNC, smoking and alcohol
abuse [3], are associated with sleep disturbances in the generalstic and statistical manual of
r research and treatment of
al classification of sleep dis-
y e head and neck module;
phy; PSQI, Pittsburgh sleep
je Universiteit Amsterdam,
ery, P.O. Box 7057, 1007 MB
I.M. Verdonck-de Leeuw).population [4,5]. Patients with HNC also often experience specific
symptoms which may be associated with their disease and treat-
ment phase, for example xerostomia (dry mouth) and pain in the
mouth/throat area [6]. These symptoms are known to be strong
predictors of sleep disturbances among HNC patients [7]. Moreover,
being diagnosed with and treated for HNC is stressful. Previous
studies have demonstrated that psychological distress including
symptoms of anxiety and depression among HNC patients is highly
prevalent [8,9] and is associated with sleep disturbances [10].
According to the third edition of the international classification
of sleep disorders (ICSD-3), there are sevenmajor diagnosis of sleep
disorders: 1) insomnia, 2) sleep-related breathing disorders, 3)
central disorders of hypersomnolence, 4) circadian rhythm sleep-
wake disorders, 5) parasomnias, 6) sleep-related movement dis-
orders, and 7) other sleep disorders [11]. The diagnosis of these
sleep disorders is based on subjective measures, such as sleep di-
aries, interview, sleep consultation, and questionnaires, as well as
objective measures, such as polysomnography (PSG) and
A.M.M. Santoso et al. / Sleep Medicine Reviews 47 (2019) 62e73 63actigraphy [12]. Among these distinct types of sleep disturbances,
insomnia, hypersomnolence, and sleep-related breathing distur-
bances are expected to be commonly experienced by HNC patients.
Firstly, insomnia entails difficulties falling or staying asleep or
sleep of poor quality, leading to daytime disabilities [13]. Insomnia
is the most common type of sleep disturbances among the general
population [12]; this problem is even more prevalent in cancer
patients [14]. Secondly, hypersomnolence is characterized by
excessive daytime sleepiness and only diagnosed in the absence of
other sleep disorders which might cause insufficient sleep and
hence more sleepiness during the day. However, in cancer patients
hypersomnolence is often reported as a symptom while the exact
cause is unknown [15]. Factors found to be related to hypersom-
nolence are, for example, radiotherapy, chemotherapy, and opiates
(i.e., a commonly prescribed pain-relieving medication among HNC
patients) [16e19]. Finally, obstructive sleep apnea (OSA), one of the
most prominent form of sleep-related breathing disturbances, in-
volves frequent breathing pauses due to narrow or obstructed up-
per airways [20]. HNC patients are at risk for this condition because
the pharyngeal and craniofacial structures are often altered due to
cancer itself or its treatment side effects.
Despite its importance, precise estimates of the prevalence of
sleep disturbances among HNC patients are lacking [21]. Previous
reviews reported prevalence rates ranging from 8% to 100% among
cancer patients [22e25]. To the extent of our knowledge, no meta-
analysis has been performed on the prevalence of all different types
of sleep disturbances among HNC patients. Therefore, the aim of
this study is to systematically review the prevalence of all types of
sleep disturbances among HNC patients before, during, and after
treatment using meta-analysis approach.
Methods
Literature search
The search strategy was part of another systematic review
which examined sleep disturbances among mixed cancer patients
(Prospero ID CRD42018088119) [26]. A comprehensive search was
performed in the following bibliographic databases: Pubmed,
Embase, CINAHL, and PsycINFO. Databases were searched from
inception up to November 2017. Synonyms and closely related
words were searched as index terms or free-text words for the
following terms: cancer (e.g., cancer, malignancy, and carcinoma),
sleep disturbances (e.g., sleep problems, disturbed sleep, para-
somnia, hypersomnolence, and circadian rhythm disturbance), and
epidemiological studies (e.g., epidemiological studies, cross-
sectional, and observational). All terms related to distinct forms
of sleep disturbance, based on the ICSD-3, as well as different index
terms for each bibliographic database were listed. The complete
description of our search strategy is available in Appendix 1.
An information specialist from the medical library (de Vries R)
provided advice on the literature search. Additional relevant full-
texts were hand-searched from the reference list of the included
studies and relevant reviews.
Inclusion and exclusion criteria
Studies which met the following inclusion criteria were
included in this systematic review: 1) measuring any type of sleep
disturbances, 2) including HNC patients, 3) reporting the preva-
lence of sleep disturbances among HNC patients, and 4) full-text in
English. Studies with all treatment modalities (surgery, radio-
therapy, chemotherapy, combination, treatment with curative
intent, or palliative treatment), phase of treatment (before, during,
or after treatment), and any study design were included. Case-reports, narrative studies, study protocols, conference abstracts,
editorials, and systematic reviews were excluded. The prevalence
did not have to be the primary aim of the study.
Screening and selection of relevant articles
Two independent reviewers (Santoso AMM and Jansen F) each
screened titles and abstracts after previously removing all dupli-
cates from the search results. Titles and abstracts which were
clearly not relevant (e.g., focusing on patients with benign tumors,
non-adult populations, or animal studies) were excluded. Full-texts
of the remaining references were retrieved. Subsequently, relevant
full-texts were selected based on the inclusion and exclusion
criteria. Disagreements were discussed andwhen necessary, a third
reviewer (Verdonck-de Leeuw IM and/or van Straten A) was con-
sulted until agreement was reached.
Data extraction and quality assessment
Both data extraction and quality assessment were performed by
two independent reviewers (Santoso AMM and Jansen F). Any
disagreements between raters were discussed and when necessary,
a third reviewer (Verdonck-de Leeuw and/or van Straten A) was
consulted until consensus was reached. We extracted information
related to: study characteristics (i.e., publication year, country of
study, study design, sample size, and eligibility criteria), population
characteristics (i.e., demographics, cancer site and stage, and
treatment characteristics), sleep disturbance measures (i.e., mea-
surement instrument used and time point of measurement), and
the prevalence of sleep disturbances (i.e., overall prevalence and
prevalence among subgroups).
Each study was appraised for its methodological quality and
potential bias. We used the critical appraisal checklist developed by
the Joanna Briggs Institute [27]. In brief, this list consists of nine
items examining the quality of studies which report prevalence,
based on how the study was designed, conducted, and reported
(Table 2, footnote). Each item is answered with yes, no, unclear (i.e.,
when some information is not reported in the article), or not
applicable (i.e., when the question is not applicable to a certain
study design). We calculated the total quality score for each study
based on the total number of positively scored items. For the third
item in this list (‘Was the sample size adequate?’), we used a rec-
ommended formula to calculate minimum sample size in preva-
lence studies [28]. Using this formula, the minimum sample size
was 289 participants [28,29].
Analyses
Pooled means of prevalence rates were calculated using
Comprehensive Meta-Analysis software, version 3 (Biostat, Engle-
wood 2013). For each of the sleep disturbances, the pooled preva-
lence rate was calculated using a random effects model because it
was expected that the studies would be methodologically hetero-
geneous [29]. Heterogeneity was visually examined by inspecting
the forest plots and statistically confirmed by examining the I2
values. An I2 value of 0% indicates no observed heterogeneity
among studies, 1e25% indicates low heterogeneity, 25e75% in-
dicates moderate heterogeneity, and >75% indicate high hetero-
geneity [30]. A confidence interval of 95% was used. We also
examined the prevalence rate in a set of pre-defined groups,
namely: type of treatment (surgery, chemotherapy, or (chemo-)
radiotherapy; single therapy or multimodal therapy), phase of
treatment (before, during, or after), measurement instrument used
(i.e., among different types of questionnaire or different cut-offs),
and studies with a high quality (risk of bias assessment  5 items
A.M.M. Santoso et al. / Sleep Medicine Reviews 47 (2019) 62e7364evaluated positive). Funnel plots were generated to visually
examine the presence of publication bias, which was then statis-
tically tested by Egger's regression test and BeggeMazumdar's rank
correlation test. When publication bias seemed to be present (p-
value < 0.05), DuvaleTweedie's trim-fill test was performed to
calculate the adjusted pooled estimates. Reporting of meta-
analyses was performed according to PRISMA guidelines
(Appendix 2) [31].Results
Inclusion of studies
The search resulted in 7191 records (Fig. 1). The majority of the
records were excluded based on title and abstract screening. Full-
texts were retrieved for the remaining 87 references. Of these 87
records, 26 articles fulfilled the eligibility criteria and three addi-


















3 additional full-texts identified 
from hand-searching
Fig. 1. Flow diagram of the literresulted in 29 full-texts of accumulatively 2315 HNC patients
included in this review.Characteristics of the included studies
The majority (72%) of these studies had a cross-sectional design
[32e52]. The remaining studies had prospective observational [53]
or retrospective design [54e58]. Most studies (59%) were
conducted in the USA, Canada, or European countries
[34,35,37,39e41,43,45e48,50,52,54,57,59,60]. Twenty-one studies
focused specifically on HNC patients [32,34e36,39e42,
44e46,48,50,51,53e56,58e60], while eight studies focused on
mixed cancer diagnoses but included a separate analysis among
HNC patients. Nineteen studies (66%) primarily aimed to measure
sleep disturbances [32e36,41,42,44e48,50,51,53,55e57,60], while
the remaining studies aimed to measure various symptoms
[37e39,43,49,52,54,59], quality of life [40], or psychiatric disorders
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ature search and selection.
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the remaining included HNC patients of specific location, such as
tongue [32,40], larynx [42,51], nasopharynx [53,55,56], and
oropharynx [45]. About 33% [36] up to 93% [51] of the study pop-
ulation consists of male HNC patients, while the gender proportion
was unknown among eight studies [33,37,38,43,47,49,52,57].
Among the 29 included studies, 10 studies (34%) measured more
than one types of sleep disturbances [33,34,36,39,40,44,45,50,51,59].
The included studies used a variety of definitions and instruments to
report on sleep disturbances. The studies were grouped into three
categories. The first category was insomnia and consisted of 17
studies [33,34,37,39,40,43e45,47,49,52,54e59]. The studies used
either self-reported insomnia symptoms (including poor sleep
quality, disturbed sleep, and trouble falling asleep) as well as inter-
view- and diagnostic and statistical manual of mental disorders
(DSM)-based insomnia diagnosis. Self-reported insomnia symptoms
were measured by questionnaires in 14 studies, of which four
studies used the Pittsburgh sleep quality index (PSQI) with various
cut-off scores [34,44,55,56], two studies used MD Anderson symp-
tom inventory e head and neck module (MDASI-HN) [39,59], two
studies used the European organization for research and treatment
of cancer (EORTC) questionnaire [43,52], one study used the Ham-
ilton depression inventory [47], and five studies used either a study-
specific questionnaire or used a known questionnaire but did not
report the cut-off score [37,40,45,49,54]. One study used multiple
definitions of self-reported insomnia symptoms (i.e., insomnia
measured by insomnia severity index [ISI] with unknown cut-off
and poor sleep quality measured by PSQI with cut-off of 5) [33].
The DSM-based diagnosis of insomnia was measured by structured
interview in two studies [57,58].
The second category was hypersomnolence and consisted of 12
studies [33,34,36,38e40,44,45,49e51,59]. Studies on excessive
daytime sleepiness and drowsiness were included in this category.
A slight majority of the studies (58%) used the Epworth sleepiness
scale (ESS) to measure daytime sleepiness, although with
various cut-offs or without pre-defined cut-off scores
[33,34,36,44,45,50,51]. The remaining studies used various in-
struments to measure drowsiness, namely the MDASI-HN [39,59],
Edmonton symptom assessment scale [38,49], or Memorial
symptom assessment scale [40].
The third categorywas sleep-related breathing disturbances and
consisted of 14 studies [32,34e36,41,42,44e46,48,50,51,53,60]. We
included studies on OSA and OSA-related symptoms into this
category. Polysomnography (PSG) was used in the majority of
studies (n ¼ 10, 71%) [32,34e36,42,46,48,51,53,60] to establish the
diagnoses, while three studies used home sleep testing [41,45,50].
Questionnaires and interviews were used to measure symptoms
such as snoring and choking/gasping during sleep [44e46,50].
We found no studies reporting on the prevalence of the
remaining types of sleep disturbances, such as circadian rhythm
sleepewake disorder, parasomnia, or sleep-related movement
disorders.
Three studies did not report details related to treatment phase
[37,38,43]. Among the studies that provided details on treatment
phase, three studies reported sleep disturbances before the start of
treatment [39,56,60], two studies during treatment [33,47], 12
studies after treatment [32,35,36,40e42,44e46,48,50,51], five
studies included patients whowere either before or after treatment
[53,55,57e59], and two studies reported sleep disturbances among
patients who are undergoing treatment or who have finished their
treatment [34,52]. In general, these studies included patients with
curative treatment, although not all studies provided detailed in-
formation on treatment intent. Three studies reported sleep dis-
turbances during palliative treatment [49,52,54]. More details on
the characteristics of the included studies are presented in Table 1.Quality and risk of bias assessment
The quality and risk of bias assessment is presented in Table 2.
Only one study (3%) had a sufficient sample size (i.e., 289 par-
ticipants) [39]. A majority of the studies (86%) had a sample size of
less than 100 HNC patients [32e36,38,40e53,55e58,60]. Two
studies (7%) scored positive on the item about response rate
[39,53]. The remaining studies scored negative as they had a
response rate of less than 70% and did not report on the charac-
teristics of non-responders versus responders, which hampers the
ability to assess whether non-response might have affected the
prevalence rate. Nineteen studies (66%) used validated sleep
disturbance instruments or established diagnosis criteria of sleep
disturbance [32,33,36,38,39,41,42,44,46,48,49,51,53,55e60], while
the remaining studies used either study-specific questionnaires or
instruments not specifically validated to measure sleep distur-
bances. Seventeen studies (59%) performed appropriate statistical
analysis [32,35,41,42,44e48,50,51,53e55,57,58,60] which is
defined as providing correct prevalence rates including the total
number of patients screened on sleep disturbances and the actual
number of patients with sleep disturbances. On average, studies
had three positively marked items, ranging from one [34] to five
[39,41,52,55,56,58,59].
Prevalence of insomnia
The pooled prevalence of insomnia was 29%, 45%, and 40%
before, during, and after curative treatment, respectively (Table 3).
During palliative care, the pooled prevalence is 52%. Before and
after treatment, the prevalence of self-reported symptoms of
insomnia was 30% and 46%, respectively, while the prevalence of a
DSM-based diagnosis of insomnia disorder was 21% and 23%,
respectively. When self-reported insomnia was defined with PSQI
cut-off of 5, the pooled prevalence was 37% before and 75% after
treatment. The comparison of pooled prevalence rates after
different type of treatments was not possible since only two studies
reported the prevalence rates after surgery only and one study
reported the prevalence after chemotherapy only; the remaining
studies were performed among HNC patients after various combi-
nations of treatment.
Prevalence of hypersomnolence
The pooled prevalence of hypersomnolence was 16% before and
32% after curative treatment (Table 4). The prevalence rate of hy-
persomnolence during curative and palliative treatment was re-
ported by each one study, which was 35% and 86%, respectively.
When defined with ESS cut-off of 10, the pooled prevalence of
sleepiness was 39%. The pooled prevalence of drowsiness measured
by various instruments was 21%.
Prevalence of sleep-related breathing disturbances
The pooled prevalence of sleep-related breathing disturbances
was 66% before and 51% after curative treatment (Table 5). No study
reported the prevalence of sleep-related breathing disturbance
during either curative or palliative treatment. After treatment, the
pooled prevalence was 71% (apneaehypopnea index [AHI] cut-off
score of 5), 47% (AHI cut-off score of 15), and 37% (when defined
as snoring). With respect to treatment modality, the pooled prev-
alence rate was 67% among patients who underwent surgery with
(chemo-) radiotherapy, 58% among patients who underwent sur-
gery alone, and 50% among patients who underwent chemo-
radiotherapy only.
Table 1
Overview of included studies (ordered alphabetically by first author's name).
Author, year Country Design Primary aim HNC site n Age (years) Men (%) Time since diagnosis, treatment






Chan et al., 2012 [32] Taiwan Cross-sectional Determine the prevalence of OSA in
patients with primary squamous cell
carcinoma of the tongue who
underwent resection and/or RT.
Tongue 26 Mean 52
(32e71)
92 6 mo to 11 y after treatment.
Neck dissection 85%, RT 65%
OSA, PSG, AHI  5
Echchikhi et al., 2017 [33] Morocco Cross-sectional Determine prospectively the
prevalence of sleep disorders, especially
insomnia among patients with cancer
receiving chemo and/or RT.
Unspecifieda 41 Specific for HNC is not
reported
Undergoing treatment. Surgery,








Faiz et al., 2014 [34] USA Cross sectional Describe characteristics of sleep
disorders in patients with HNC referred
for evaluation based on PSG data;
determine the risk factors and
symptoms that suggest underlying
sleep-related breathing disorder





OSA, PSG, AHI > 5
Sleepiness, ESS  10
Friedman et al., 2001 [35] USA Cross sectional Identify incidence of OSA in patients
with HNC treated by surgical resection








88 After surgery 100%, received RT
42%
OSA, PSG, RDI > 15
Gilat et al., 2013 [36] Israel Cross-sectional Evaluate quality of sleep and the rate of
sleep-disordered breathing in patients
treated for tongue cancer with radial
forearm free flap reconstruction.
Tongue 15 Mean 57
(27e79)
33 Mean time from treatment
completion (including
postoperative therapy):
4.9 y (range 2e6 y). After
surgery (tongue dissection and
elective neck
dissection) ¼ 100%.
OSA, PSG, AHI > 5
Sleepiness ESS  8
Grond et al., 1993 [54] Germany Prospective
observational
Assess the causes and mechanisms of
pain and to evaluate the efficacy and











167 58 ± 11 70 Before pain treatment (100%).
Undergone RT 80%, undergone
surgery 63%, undergone chemo










Grond et al., 1994 [37] Germany Cross-sectional Evaluate the prevalence of 15 important
symptoms and symptom groups in
cancer of different sites.
Unspecifieda 236 Specific for HNC is not
reported
At time of referral to the pain
clinic for treatment of
“intractable” pain. Treatment
phase for HNC subsample not
reported, but the majority of all
cancer patients is palliative.
Insomnia, unspecified
questionnaire
Gunn et al., 2013 [59] USA Cross-
sectionalb
Examine the pattern of symptoms
experienced by patients with HNC
before planned RT or CRT
Unspecified 270 Median 59
(SD 11.9)
76 Median days from last day
chemo 21.6 (SD 25.3), from
surgery to completion of
MDASI-HN: 39.1 d (SD 25.7).
Before starting curative RT-
based treatment (100%). Prior
chemo 26.7%, prior surgery 29%.
Disturbed sleep MDASI-
HN  5 (moderate to
severe)
Drowsiness MDASI-



















Gupta et al., 2016 [38] India Cross-sectional Assess presence and severity of various
symptoms among critically ill cancer
patients at the time of admission to an
intensive care unit.
Unspecifieda 26 Specific for HNC is not
reported
Not reported Drowsiness ESAS, cut-
off unknown
Hanna et al., 2015 [39] USA Cross-sectional Assess and explore symptom severity
and interference in treatment-naive
HNC patients.
Unspecified 748 Median 59
(SD 14.6)
68 Had no prior cancer therapy
(100%)
Disturbed sleep MDASI-
HN  5 (moderate to
severe)
Drowsiness MDASI-
HN  5 (moderate to
severe)
Harrison et al., 1997 [40] USA Cross-sectional Evaluate quality of life in patients
treated with primary RT for cancer of
the base of tongue.
Base of tongue 29 58 (35e71) 81 Median follow-up 5 y (min. 3 y).





Huyett et al., 2017 [41] USA Cross-sectional Assess the prevalence of OSA in HNC
patients treated with RT or CRT for




16 62 (48e75) 81 >3 mo after RT or CRT (100%),
no active or recurrent disease
OSA, HST, AHI  5
Israel et al., 2006 [42] Brazil Cross-sectional Assess occurrence and severity of OSA
in patients undergoing laryngectomy
for the treatment of laryngeal
carcinoma.
Larynx 22 Mean 66
(50e80)
91 Underwent laryngectomy in
the last 6 y (100%)
OSA, PSG, AHI  15,
moderate to severe
Johnsen et al., 2009 [43] Denmark Cross-sectional Measure symptoms and problems in
advanced cancer patients and identify
the predictors.
Unspecifieda 72 Specific for HNC is not
reported
Diagnosis/treatment




Li et al., 2017 [44] Japan Cross-sectional Provide a detailed description of the
characteristics of sleep disturbance in
long-term HNC survivors.
Unspecified 77 Mean 68
(28e86)
68 3 y after surgical treatment
(100%)
Poor sleep quality,
PSQI  5 and PSQI  8
Snoring, PSQI
Sleepiness, ESS 10
Lin et al., 2014 [53] Taiwan Retrospective Assess changes in respiratory sleep
indexes, sleep architecture, and
daytime somnolence before and after
treatment in patients with
nasopharyngeal cancer.
Nasopharynx 18 Mean 50 83 Before curative treatment
(Chemo) RT ¼ 100%
OSA, PSG, AHI  5,
AHI  15 (moderate or
severe)
Loth et al., 2017 [45] France Cross-sectional Evaluate the rate of OSA in a population
of patients treated for an advanced
oropharyngeal cancer.
Oropharynx 51 Mean 6 (44
e76)
73 12 mo post treatment.
Combined chemo 80%, surgery
and CRT 20%. Mean time
between end of treatment and
sleep disturbance




OSA, HST AHI > 10
Sleepiness, ESS  10
Mo et al., 2014 [55] China Prospective
observational
Explore cognitive function, and
prevalence of depression, anxiety and
sleep changes in nasopharyngeal
carcinoma patients.
Nasopharynx 51 Mean 40
(24e60)
63 After diagnosis (before
treatment started) ¼ 100%
Poor sleep quality,
PSQI > 5
Nesse et al., 2006 [46] The Netherlands Cross-sectional Identify the prevalence of OSA within a






70 6-mo to 5 y post curative
treatment (100%). Surgery 39%,
Surgery and RT 39%, RT 22%
OSA, PSG AHI  5
OSA-related
complaints, ESS  10 or
2 study-specific items
Palesh et al., 2010 [47] USA Cross-sectional Determine prospectively the
prevalence of insomnia among patients
with cancer receiving chemo.
Unspecifieda 4 Specific for HNC is not
reported
Starting chemo (100%) Clinical insomnia HDI,
cut-off based on DSM-
IV
Payne et al., 2005 [60] Canada Cross-
sectionalb
Determine the prevalence of OSA
among patients with malignant tumors
of the oral cavity and oropharynx prior
to primary surgical resection.
Oral cavity or
oropharynx
17 64 ± 2 82 Before surgery (100%), range 2
e14 d
OSA, PSG AHI  15


















Table 1 (continued )
Author, year Country Design Primary aim HNC site n Age (years) Men (%) Time since diagnosis, treatment






Qian et al., 2010 [48] Canada Cross-sectional Determine the point prevalence of sleep









67 6 mo after completion
primary treatment; no residual
or recurrent disease (100%)
OSA PSG RDI  15
(moderate and severe)
OSA PSG RDI  5 (all
severity)
Qin et al., 2015 [56] China Prospective
observational
Examine sleep and psychological
characteristics in patients with local-
advanced nasopharyngeal carcinoma
following IMRT completion and
concurrent chemo.
Nasopharynx 60 39.8 ± 8.9 62 After diagnosis, before IMRT
started (100%); (2 cycles
concurrent chemo 33%, 3 cycles
of concurrent therapy 67%)
Poor sleep quality,
PSQI > 5
Savard et al., 2011 [57] Canada Prospective
observational
Assess the prevalence and natural
course of insomnia comorbid with
cancer during an 18-month period in
patients undergoing treatment for non-
metastatic cancer
Unspecifieda 59 Specific for HNC is not
reported
Before curative surgery (100%) Insomnia symptoms, IIS
based on DSM-IV
criteria
Shao et al., 2016 [49] China Cross-sectional To identify prevalence and severity of
non-pain symptoms and to clarify
possible influences on each non-pain
symptom.
Unspecifieda 14 Specific for HNC is not
reported
Palliative 100%, immediately






Steffen et al., 2009 [50] Germany Cross-sectional Assess the prevalence of OSA in HNC







71 Within 2 y of last aftercare visit,
but more than 6 mo after last
surgical and/or adjuvant
therapy.
OSA, HST AHI  20
snoring, interview
Sleepiness, ESS  10
Teixeira et al., 2013 [51] Brazil Cross-sectional Compare the prevalence and severity of
OSA in patients undergoing
laryngectomy.
Larynx 14 68 (41e84) 93 After partial laryngectomy
(100%), mean time after end of
treatment 54 mo (6e84 mo)
OSA, PSG AHI 5e30
(mild)
OSA, PSG AHI > 30
(severe)
OSA, PSG AHI > 5 (all
severity)
Sleepiness, ESS > 10
Unal et al., 2016 [58] Turkey Prospective
observational
Evaluate the effects of RT on psychiatric
disorder in HNC patients.
Unspecified 51 57.6 ± 11.2 90 Before RT Sleep disorder,
interview DSM-IV
van den Beuken-van
Everdingen et al., 2009 [52]
The Netherlands Cross-sectional To measure the prevalence of non-pain
physical symptoms and psychological
symptoms in patients with cancer.
Unspecifieda 63 Specific for HNC is not
reported
Curative 62% (of which
64% >6 mo after treatment, 36%






Abbreviations: AHI: apneaehypopnea index; Chemo: chemotherapy; CRT: chemoradiotherapy; DSM-IV: diagnostic and statistical manual of mental disorders, fourth edition; EORTC: European organization for research and
treatment of cancer; ESAS: Edmonton symptom assessment scale; ESS: Epworth sleepiness scale; HDI: Hamilton depression inventory; HNC: head and neck cancer; HST: home sleep test; IIS: insomnia interview schedule; IMRT:
intensity modulated radiotherapy; ISI: insomnia severity index; MDASI-HN: MD Anderson symptom inventory e head and neck module; MSAS: Memorial symptom assessment scale; OSA: obstructive sleep apnea; PSG:
polysomnography; PSQI: Pittsburgh sleep quality index; RDI: respiratory disturbance index; RT: radiotherapy; SD: standard deviation.
Note: Age was denoted in mean ± standard deviation (SD) or median (range), otherwise noted. All percentages are rounded.
a The study focused on mixed cancer patients. Sleep disturbances among head and neck cancer (HNC) patients were reported.



















Quality and risk of bias appraisal of included studies (ordered alphabetically by first author's name).
Author Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Total positive score
Chan et al., 2012 [32] Y U N N U Y U Y U 3
Echchikhi et al., 2017* [33] N Y N N U Y Y N U 3
Faiz et al., 2014 [34] N Y N N U U N N N 1
Friedman et al., 2001 [35] Y N N N U U U Y U 2
Gilat et al., 2013 [36] Y Y N Y U Y U N U 4
Grond et al., 1993 [54] Y Y N N U U U Y U 3
Grond et al., 1994* [37] Y Y N U U U U N U 2
Gunn et al., 2013 [59] Y Y N Y U Y Y N U 5
Gupta et al., 2016* [38] Y U N U U Y N N U 2
Hanna et al., 2015 [39] Y U Y Y Y Y U N NA 5
Harrison et al., 1997 [40] U U N Y U U Y N U 2
Huyett et al., 2017 [41] Y U N Y U Y Y Y U 5
Israel et al., 2006 [42] Y U N Y U Y U Y N 4
Johnsen et al., 2009* [43] Y N N U U U Y N N 2
Li et al., 2017 [44] N N N N U Y U Y U 2
Lin et al., 2014 [53] N U N N Y Y Y Y NA 4
Loth et al., 2017 [45] Y Y N Y U U U Y U 4
Mo et al., 2014 [55] N U N Y U Y Y Y Y 5
Nesse et al., 2006 [46] N Y N Y U Y U Y N 4
Palesh et al., 2010* [47] Y U N U U U Y Y U 3
Payne et al., 2005 [60] Y N N N U Y Y Y U 4
Qian et al., 2010 [48] Y U N Y U Y U Y N 4
Qin et al., 2015 [56] Y Y N Y U Y U N Y 5
Savard et al., 2011* [57] N U N U U Y Y Y U 3
Shao et al., 2016* [49] N Y N N U Y Y N U 3
Steffen et al., 2009 [50] Y Y N N U U U Y U 3
Teixeira et al., 2013 [51] Y Y N Y U Y U Y N 5
Unal et al., 2016 [58] Y U N Y U Y Y Y U 5
van den Beuken-van
Everdingen et al., 2009* [52]
Y U N U U U Y N U 2
Note:
1. Q1e9: questions to assess study quality and risk of bias, as listed below
Q1: Was the sample frame appropriate to address the target population?
Q2: Were study participants sampled in an appropriate way?
Q3: Was the sample size adequate?
Q4: Were the study subjects and the setting described in detail?
Q5: Was the data analysis conducted with sufficient coverage of the identified sample?
Q6: Were valid methods used for the identification of the condition?
Q7: Was the condition measured in a standard, reliable way for all participants?
Q8: Was there appropriate statistical analysis?
Q9: Was the response rate adequate, and if not, was the low response rate managed appropriately?
2. Y, yes, highlighted; N, no; U, unclear; NA, not applicable.
3. Studies marked with asterisk (*) focused on mixed cancer patients, but sleep disturbances among head and neck cancer patients were reported. For these studies the items
“Were the study subjects and the setting described in detail?” and “Was the data analysis conducted with sufficient coverage of the identified sample?” were scored as
“Unclear”.
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Publication bias was examined on the prevalence of insomnia
during treatment (p-value > 0.05), insomnia after treatment (p-
value < 0.05), and sleep-related breathing disturbances after
treatment (p-value < 0.05). Random effects model of DuvaleTwe-
edie's test resulted in the adjusted pooled estimates of 50% for
insomnia during treatment, 47% for insomnia after treatment, and
40% for sleep-related breathing disturbances after treatment
(Tables 3 and 5). We did not examine publication bias on the other
sleep disturbances before and after treatment because the number
of studies was too small (i.e., less than three studies).Discussion
In this systematic review and meta-analysis investigating the
prevalence of sleep disturbances among HNC patients, we found 29
studies measuring three types of sleep disturbances: insomnia,
hypersomnolence, and sleep-related breathing disturbances. No
studies were found investigating circadian rhythm sleepewake
disorders, parasomnias, or sleep-related movement disorders,
despite our extensive search strategy. The pooled prevalence ofinsomnia was 29% before treatment, 45% during treatment (50%
after correcting for publication bias), and 40% after treatment (47%
after correcting for publication bias). The pooled prevalence of
hypersomnolence was 16% before and 32% after treatment. For
sleep-related breathing disturbances, the pooled prevalence was
66% before and 51% after treatment (40% after correcting for pub-
lication bias). Only one study reported the prevalence of HNC pa-
tients who had both sleep-related breathing disturbance and
hypersomnolence [45], hence we were unable to confirm whether
the prevalence rate of hypersomnolence overlaps with that of
sleep-related breathing disturbance.
The prevalence of sleep disturbances before the start of HNC
treatment (16e66%) is notably higher compared to that of the
general population (2e38%) [61,62]. Tumor mass effect of HNCmay
cause obstruction around tongue, pharynx, and epiglottis, the most
common sites involved in OSA [63]. In addition, anxiety and
depression are highly prevalent at the time of HNC diagnosis [8,9]
which may also contribute to insomnia. People recently con-
fronted with the diagnosis of HNC may experience fear and un-
certainty related with HNC treatment and its outcome [64]. Such
uncertainty may affect their social situations and sleepewake
patterns. Furthermore, two major risk factors of HNC, alcohol
Table 3
Prevalence rates of insomnia.
Characteristics N study Cumulative rates Pooled estimatea 95% CIa Heterogeneity
I2 Q-stats p-value
Before treatment, all [39,55e59] 6 355/1093 0.29 0.20e0.41 86.16 36.12 <0.001
Study design
 Good quality studies (5 positive items) [39,55,56,58,59] 5 326/1034 0.26 0.16e0.38 86.3 29.19 <0.001
Definition of insomnia
 Self-reported insomnia, all [39,55,57,59] 4 323/983 0.30 0.21e0.41 82.48 17.12 0.001
 Poor sleep quality: PSQI > 5 [55,56] 2 41/111 0.37 0.29e0.46 0 0 1
 Disturbed sleep: MDASI-HN  5 [39,59] 2 282/872 0.25 0.11e0.48 93.9 16.39 <0.001
 DSM-based diagnosis of insomnia [57,58] 2 33/110 0.21 0.02e0.80 94.49 18.15 <0.001
During treatment, all [33,47,52] 3 26/59 0.45 0.33e0.58 0 1.39 0.500
Adjusted estimates (publication bias)b NA NA 0.50 0.38e0.61 NA NA NA
After treatment, all [40,44,45,52,55,57e59] 8 168/395 0.40 0.24e0.58 89.35 65.73 <0.001
Study design
 Good quality studies (5 positive items) [55,58,59] 3 50/173 0.25 0.05e0.67 94.81 38.50 <0.001
Definition of insomnia
 Self-reported insomnia, all [40,44,45,52,55,59] 6 144/304 0.46 0.28e0.65 88.86 44.89 <0.001
 PSQI  5 [44,55] 2 97/128 0.75 0.54e0.89 80.92 5.24 0.022
 DSM-based diagnosis of insomnia [57,58] 2 24/91 0.23 0.03e0.78 92.34 13.06 <0.001
Treatment type
 Surgery only [57,59] 2 33/114 0.31 0.09e0.67 94.81 38.5 0.004
 Single treatmentc [55,57,59] 3 66/162 0.43 0.16e0.75 92.20 25.63 <0.001
Adjusted estimates (publication bias)b NA NA 0.47 0.28e0.66 NA NA NA
Palliative care, all [49,52] 2 16/38 0.52 0.04e0.97 92.32 13.02 <0.001
Unknown phase of treatment, all [37,43] 2 182/308 0.54 0.34e0.73 89.79 9.80 0.002
Abbreviations: CI, confidence interval; DSM, diagnostic and statistical manual of mental disorders; MDASI-HN, MD Anderson symptom inventory e head and neck module;
NA, not applicable; PSQI, Pittsburgh sleep quality index.
Note:
a Pooled estimate and 95% CI were analyzed using random effects model.
b Adjusted values generated using DuvaleTweedie's trim and fill test, random effects model.
c Single treatment including either surgery only or chemotherapy only.
Table 4
Prevalence rates of hypersomnolence.
Characteristics N study Cumulative rates Pooled estimatea 95% CIa Heterogeneity
I2 Q-stats p-value
Before treatment, all [39,59] 2 177/872 0.16 0.07e0.32 88.78 8.91 0.003
After treatment, all [36,40,44,45,50,51,59] 7 90/275 0.32 0.20e0.48 80.40 30.61 <0.001
Study design
 Good quality studies (5 positive items) [51,59] 2 13/85 0.18 0.07e0.38 58.36 2.40 0.121
Definition of hypersomnolence
 Sleepiness: ESS  10 [44,45,50,51] 4 64/148 0.39 0.23e0.58 71.81 10.64 0.014
 Drowsiness [40,59] 2 19/100 0.21 0.07e0.49 82.91 5.85 0.016
Treatment type
 Surgery only [51,59] 2 10/88 0.15 0.04e0.45 77.83 4.51 0.034
 Single treatmentb [51,59] 2 11/85 0.18 0.07e0.38 58.36 2.40 0.121
Abbreviations: CI, confidence interval; ESS, Epworth sleepiness scale.
Note:
a Pooled estimate and 95% CI were analyzed using random effects model.
b Single treatment including either surgery only, chemotherapy only or radiotherapy only.
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lence of sleeping disturbances among HNC patients. Heavy alcohol
users often experience insomnia even after they stop their alcohol
consumption [65], while smokers suffer more insufficient sleep
compared to non-smokers [66]. Moreover, smoking damages
oropharyngeal mucosal structure [67] and this may contribute to
the relationship of smoking with sleep-related breathing distur-
bances in patients with HNC.
The evidence on the high prevalence of sleep disturbances
during treatment was based on only two studies investigating
insomnia [49,52] and one study investigating hypersomnolence
[33], with pooled prevalence of 45% and 35%, respectively. Cancer
treatment is physically and psychologically burdensome for HNC
patients due to the treatment-related side-effects. HNC patients
who are undergoing (chemo-) radiotherapy often experiencemucositis-related symptoms such as xerostomia and oral pain, as
well as fatigue, drowsiness, and nausea [7,68]. These symptoms
may cause circadian rhythm changes among HNC patients and may
contribute to the high prevalence of insomnia and hypersomno-
lence during treatment. Moreover, one out of five HNC patients
continues smoking or drinking alcohol during cancer treatment
[69] whichmay worsen their sleep problems. Pain-relievers such as
opioids are also often prescribed during cancer treatment and may
result in sleepewake rhythm changes [16,17]. So far, however, only
a limited number of studies reported on the prevalence of sleep
disturbances during HNC treatment, therefore warranting addi-
tional studies.
The prevalence rates of sleep disturbances after treatment were
also high: 40%, 32%, and 51% on insomnia, hypersomnolence, and
sleep-related breathing disturbances, respectively. This might be
Table 5
Prevalence rates of sleep-related breathing disturbances.
Characteristics N study Cumulative rates Pooled estimatea 95% CIa Heterogeneity
I2 Q-stats p-value
Before treatment, allb [53,60] 2 23/35 0.66 0.44e0.82 34.05 1.52 0.22
After treatment, all [32,34e36,41,42,44e46,48,50,51,53] 13 168/375 0.51 0.34e0.67 83.51 72.77 <0.001
Study design
 OSA as exclusion criteria [32,36,41,45,48] 5 65/117 0.53 0.43e0.63 0 3.36 0.499
 Good quality studies (5 positive items) [41,51] 2 21/30 0.76 0.20e0.98 79.87 4.97 0.026
Definition of sleep-related breathing disturbances
 OSA: AHI  5 [32,34,36,41,42,46,48,51,53] 9 139/205 0.71 0.48e0.86 83.76 49.25 <0.001
 OSA: AHI  15 [35,42,48,53] 4 37/68 0.47 0.34e0.61 56.42 6.89 0.076
 OSA: AHI  30 [42,45,51] 3 18/87 0.21 0.14e0.31 0 0.08 0.959
 Snoring [44,45,50] 3 57/159 0.37 0.09e0.77 94.97 39.77 <0.001
Treatment type
 Surgery only [32,35,42,48,50,51] 6 45/93 0.58 0.30e0.82 76.83 21.58 0.001
 Chemoradiotherapy only [48,53] 2 14/27 0.50 0.33e0.76 47.82 1.92 0.166
 Surgery with (chemo)radiotherapy [32,35,48] 3 26/39 0.67 0.36e0.88 57.75 4.73 0.094
 Single treatmentc [32,34,35,42,48,50,51] 7 84/137 0.65 0.37e0.85 81.48 32.4 <0.001
 Combination treatmentd [32,35,45,48,53] 5 60/167 0.54 0.41e0.67 23.2 5.21 0.267
Adjusted estimates (publication bias)e NA NA 0.40 0.24e0.60 NA NA NA
Abbreviations: AHI, apneaehypopnea index; CI, confidence interval; NA, not applicable; OSA, obstructive sleep apnea.
Note:
a Pooled estimate and 95% CI were analyzed using random effects model.
b Pooled prevalence of OSA defined with AHI 15.
c Single treatment including either surgery only, chemotherapy only or radiotherapy only.
d Combination treatment including chemoradiotherapy (with or without other modality) and surgery with either chemotherapy or chemoradiotherapy.
e Adjusted values generated using DuvaleTweedie's trim and fill test, random effects model.
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phedema in the head and neck area, tinnitus, and dysregulation of
thyroid hormone after (chemo-) radiotherapy. The high prevalence
of insomnia may be associated with psychological symptoms such
as depression, post-traumatic stress disorders, problems with
body-image, and fear of cancer recurrence. These symptoms may
continue to be present after HNC is treated successfully [64,70e73].
In addition, radiation in the head and neck area may be associated
with sleep-related breathing disturbances in twoways: first, it may
alleviate breathing disturbances by reducing the tumor mass; and
on the other hand, it may cause scarring, airway narrowing, and
alterations of the sensory- and mechanoreceptors in the upper
airway [63].
We also found that more than a half of HNC patients receiving
palliative care reported insomnia. This high prevalence of insomnia
among patients in palliative care may be explained by the above-
mentioned causes of sleep disturbances before, during, and after
treatment of HNC, and further worsened by the advanced stage of
cancer, cancer recurrence, distant metastasis or presence of a sec-
ond primary cancer [73]. In addition, palliative care patients report
high level of anxiety [49], which affects sleep quality.
The strength of this study is that meta-analytic methods were
used to investigate the prevalence of various types of sleep dis-
turbances among HNC patients. We also presented prevalence rates
of sleep disturbances in different phases of treatment (i.e., before,
during, and after treatment) and palliative care, which resulted in a
thorough overview of studies performed so far.
We, however, also acknowledge some limitations of this study.
Considerable heterogeneity was found regarding the definition of
sleep disturbances, the used measurement instruments to assess
sleep disturbances as well as the used cut-off scores on the mea-
surement instruments. This heterogeneity was in line with previ-
ous reviews on the prevalence of sleep disturbances among mixed
cancer patients and the general population [29,61]. In addition,
only a limited number of studies were performed per subgroup ofpatients (e.g., regarding phase of treatment or type of treatment),
which hindered the ability to statistically compare prevalence rates
among these subgroups, as well as to examine differences among
countries and study years. For example, it seems that among HNC
patients, sleep-related breathing disturbances are more frequently
present than other types of sleep disturbances but this observation
needs further investigation. Also, we were only able to report the
prevalence of hypersomnolence as a symptom, as there is lack of
studies which reported hypersomnolence as a sleep disorder. Sleep
disturbances, additionally, seem to increase after treatment, but
longitudinal studies investigating the course of sleep disturbances
from diagnosis to follow-up are needed to confirm this observation.
Another limitation is that publication bias is likely to have occurred,
which may either under- or overestimate the reported prevalence
rates in this meta-analysis. We also excluded non-English articles,
which may have resulted in underrepresentation of prevalence
rates of sleep disturbances in non-English-speaking countries.
Finally, most studies were of insufficient methodological quality: a
small group of HNC patients were often included in the study,
inadequate information on their participant recruitment were
often provided, and non-validated instruments were often used to
measure sleep disturbances.
Conclusion
This systematic review and meta-analysis demonstrated that
sleep disturbances are highly prevalent at all HNC treatment
phases, underlining the importance of early screening and
tailored intervention for sleep disturbance among HNC patients.
Further studies are essential to investigate the course of sleep
disturbances from diagnosis to follow-up among both cancer
survivors and patients in palliative care. Also, more insight is
needed to understand the clinical, psychological, and life-style
related factors associated with prevalence rates among different
subgroups of HNC patients.
Research agenda
1. Perform high quality longitudinal cohort studies with
sufficient sample size on the course of sleep disturbances
over time and factors that may cause or are associated
with sleep disturbances among HNC patients over time,
including sociodemographic (e.g., sex, age), clinical
(e.g., metastasis to the brain, radiation in the head and
neck area), and lifestyle factors (e.g., BMI, physical ac-
tivity, and excessive smoking and alcohol consumption),
as well as symptoms caused by cancer and its treatment.
2. More research on sleep disturbances among HNC pa-
tients is needed worldwide. Also, when resources are
available, non-English literature should be reviewed on
the prevalence of sleep disturbances among HNC
patients.
3. Investigate possible innovations to tailor HNC treatment
and its supportive care to prevent the progression of
sleeping disturbances during and after HNC treatment.
Practice points
1. Themost commonly reported form of sleep disturbances
among HNC patients are insomnia, hypersomnolence,
and sleep-related breathing disturbances.
2. Sleep disturbances seem to be prevalent among newly
diagnosed HNC patients, suggesting the importance of
early screening for sleep disturbance already before
treatment among this population.
3. Sleep disturbances remain to be prevalent during and
after treatment, and are possibly associated with short-
term and long-term treatment side effects. Healthcare
professionals are therefore encouraged to include sleep
disturbance assessment during HNC follow-up
consultations.
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